Diabetes prevention between RAAS inhibition and PPAR-gamma stimulation: the diabetes reduction assessment with ramipril and rosiglitazone medication (DREAM) trial.
Division of Endocrinology, Diabetes and Hypertension, State University of New York Health Science Center and Kings County Hospital Center, Brooklyn, NY 11203, USA. smcfarlane@downstate.edu
Samy I
SI
McFarlane
Alfrede
A
Provilus
John J
JJ
Shin
D000959:Antihypertensive Agents / Q000627:therapeutic use*; D003924:Diabetes Mellitus, Type 2 / Q000517:prevention & control*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011236:Prediabetic State / Q000188:drug therapy*; D017257:Ramipril / Q000627:therapeutic use*; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000627:therapeutic use*
D000959:Antihypertensive Agents; D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D000077154:Rosiglitazone; D017257:Ramipril